Schlingensiepen, Karl-Hermann and Schlingensiepen, Reimar and Steinbrecher, Andreas and Hau, Peter and Bogdahn, Ulrich and Fischer-Blass, Birgit and Jachimczak, Piotr Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine & growth factor reviews 17 (1-2), pp. 129-139.
Download (882Kb) - Repository staff only
TGF-beta overexpression is a hallmark of various malignant tumors. This is due to the pivotal role of TGF-beta as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. We have developed a new immunotherapeutic approach for the treatment of malignant tumors based on the specific inhibition of TGF-beta2 by the antisense oligodeoxynucleotide AP 12009. After providing preclinical proof of concept, we assessed safety and efficacy of AP 12009 in clinical phase I/II open-label dose escalation studies in high-grade glioma patients. Median survival time after recurrence exceeded the up to date literature data for chemotherapy. A phase I/II study in pancreatic carcinoma and malignant melanoma is currently ongoing. Our results implicate targeted TGF-beta2 suppression as a promising therapeutic approach for malignant tumor therapy.
|Institutions:||Medicine > Lehrstuhl für Neurologie|
|Keywords:||TGF-β; High-grade gliomas; Pancreatic carcinoma; Malignant melanoma; Antisense oligodeoxynucleotides|
|Subjects:||600 Technology > 610 Medical sciences Medicine|
|Refereed:||Yes, this version has been refereed|
|Created at the University of Regensburg:||Unknown|
|Deposited On:||08 Dec 2006|
|Last Modified:||20 Jul 2011 22:50|